Stock Quote
NASDAQBSTC

BioSpecifics Technologies Corp. to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference

Sep 20, 2017

LYNBROOK, N.Y., Sept. 20, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 2017 Cantor Fitzgerald Global Healthcare Conference at 2:15 p.m. ET on Wednesday, September 27, 2017 in New York, NY. This is an updated time from what was previously announced in a press release issued by the Company on September 5th, 2017.

BioSpecifics Technologies Corp. Logo

A live audio webcast of each presentation can also be accessed under the "Events and Presentation" tab in the Investors section of the Company's website at www.biospecifics.com or at http://wsw.com/webcast/cantor6/bstc. An archived replay of the webcast will be available for 30 days after the live event concludes.

About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for thirteen clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and for Peyronie's disease in Europe and Australia. Endo is partnered with Sobi, Actelion and Asahi Kasei for Dupuytren's contracture and Peyronie's disease outside the U.S. The XIAFLEX research and development pipeline includes several additional promising indications. BioSpecifics is managing the development of XIAFLEX for uterine fibroids and is conducting a Phase 1 clinical trial. For more information, please visit www.biospecifics.com.

SOURCE BioSpecifics Technologies Corp.

For further information: BioSpecifics Technologies Corp. - Thomas L. Wegman, President, (516) 593-7000, thomas_wegman@biospecifics.com